CASE REPORT

Case Report: Facial mixed fungal infection in a poorly responding non-Hodgkin’s lymphoma patient with suspected immunodeficiency [version 1; peer review: 2 approved with reservations]

Ali Mostafa¹, Mervat Gaber², Hany Abdelrahman³, Noha ElAnwar¹, Ahmed Galal¹

¹Department of Pediatrics, Kasr Al Aini Faculty of Medicine, Cairo University, Cairo, Egypt
²Clinical and Chemical Pathology, Kasr Al Aini Faculty of Medicine, Cairo University, Cairo, Egypt
³Department of Pediatric Oncology, National Cancer Institute, Cairo, Egypt

First published: 07 Oct 2019, 8:1726
https://doi.org/10.12688/f1000research.20418.1
Latest published: 07 Oct 2019, 8:1726
https://doi.org/10.12688/f1000research.20418.1

Abstract
A male child presented with left lacrimal gland and right submandibular masses that were diagnosed as high grade B-cell non-Hodgkin’s Lymphoma. Immunodeficiency was suspected, mostly due to secondary to Epstein Barr virus infection. Chemotherapy was started and gradual regression was observed in the size of the lesions forming a central necrosis and facial wound. Cultures from this wound showed mixed gram negative growth of Pseudomonas aeruginosa, and Escherichia coli. Two days later, a follow up swab of the wound was taken and showed fungal growth of mixed Candida tropicalis and Cryptococcus laurentii which was treated with two antifungals (fluconazole and liposomal amphotericin B). After a second chemotherapy cycle, the facial necrotic lesion increased in size and the patient’s general condition markedly deteriorated with multi-organ system failure secondary to septic shock by candidemia. Candida glabrata, which is non-Candida albicans fungus was the fungus that appeared in the patient’s blood culture. Caspofungin was prescribed in addition to liposomal amphotericin B. Two days later, the follow up blood culture revealed growth of methicillin resistant Staphylococcus aureus and the pulmonary condition of the patient then deteriorated gradually. Six days later, the patient developed multi-organ dysfunction syndrome secondary to sepsis. We conclude that we mixed fungal infection in not uncommon among immunocompromised patients, candidemia is fatal even if treated with the correct antifungals.
Keywords
Non-Hodgkins lymphoma, immunodeficiency, candida, disseminated fungal infection, septic shock
**Introduction**

Immunocompromised patients, those with hematological malignancies, solid organ or bone marrow transplantation, are highly vulnerable to invasive fungal infection, even with administration of systemic antifungal prophylaxis\(^1\). Skin damage, which is a natural barrier and considered as one component of innate immunity, may rarely lead to fungal invasion\(^1\). Blood stream infection by *Candida* is very serious and has a mortality rate of 30–60%\(^1\). Here, we present a case of fatal mixed fungal infection that started by cutaneous mixed fungal infection that progressed to fatal candidemia.

**Case presentation**

A male patient 22 months old, 2\(^{nd}\) offspring of a consanguineous marriage (1\(^{st}\) degree relatives), presented with left lacrimal gland mass that was assumed to be an abscess (a timeline of care is given in Table 1). Empirical antibiotics (amoxicillin/calvulinic: 25 mg/kg/12 hours; for 7 days) were started but with no improvement. A week later another mass appeared at the right submandibular region, firm in consistency, adherent to the underlying tissue, with no skin infiltration. A positron emission tomography (PET)/CT scan was performed, which showed multiple nodal and soft tissue lesions at the left inner canthus infiltrating left nasal bone and lamina propria, and extending to the left orbit, right submandibular lymph nodes, bilateral scattered lung nodules, abdominal, hilar and mediastinal lymph nodes. Biopsy from the lacrimal lesion was consistent with high grade B-cell non-Hodgkin’s Lymphoma.

Full immunological assessment was done as the parents reported a history of recurrent chest infections since birth. Virology PCR for cytomegalovirus, Epstein Barr virus (EBV), herpes simplex virus and HIV was performed (only EBV was positive). The serum level of IgG (226 mg/dl; normal range 330–1260) and CD4 were low (4%; normal range at this age is 32– 51%); however other immunoglobulin levels were normal. Initial bone marrow aspirate and cerebrospinal fluid were normal with no infiltration with atypical cells.

First cycle of chemotherapy (rituximab at a dose of 12.5 mg/kg/d, cyclophosphamide at a dose of 10 mg/kg/d, methylprednisolone at a dose of 12mg/m2/d and vincristine at a dose of 0.33mg/kg/d for one day only) was started; gradual regression was observed in the size of the lesions especially the lacrimal lesion over the next 12 days. Empirical antibiotics (cefepim at a dose of 50 mg/kg/8 hours for 3 days) was added when fever neutropenia occurs at day 4 after chemotherapy.

Central necrosis started to appear at the lacrimal and submandibular lesions. Necrosis increased gradually causing exposure keratitis. Initial culture from the facial lesions showed mixed gram negative growth of *Pseudomonas aeruginosa* and *Escherichia coli*. Anti-gram negative antibiotics (meropenem at a dose of 20mg/kg/day for 32 days and amikacin at a dose of 7.5 mg/kg/12 hours for 14 days) were started. Empirical antifungal liposomal amphotericin B at a dose of 3mg/kg/day was started at the fifth day of fever neutropenia and continued for 32 days. CT paranasal sinus and chest were done as fungal screening at day 6 of chemotherapy and showed stationary pulmonary nodules and other facial and neck lesions. Serum galactomannan was negative. Three days later, a follow-up swab of the wound was taken and showed the first fungal growth of mixed *Candida tropicalis* and *Cryptococcus laurentii*. Fluconazole at a dose of 10mg/kg/day; was added to the current liposomal amphotericin B and continued for 7 days.

After 14 days of the first cycle, patient neutrophils were recovered and all culture specimen became negative with no isolated fungal growth.
microorganism. So the second cycle chemotherapy (doxorubicin at a dose 0.66 mg/kg/day for 1 day, cyclophosphamide at a dose of 25 mg/kg/day for 2 days, Rituximab at a dose of 12.5 mg/kg/d for 1 day, methylprednisolone at a dose 1.2 mg/kg/day for 5 days, and vincristine at a dose of 0.046 mg/kg/d for only one day) was given.

At day 10 of the second cycle of chemotherapy; the patient became neutropenic again and the facial necrotic lesion had increased in size and a combined surgical consultation (ophthalmology and otorhinolaryngology) decision was made to perform ethmoidectomy and enucleation to remove the source of infection whenever the general condition of the patient permitted.

Two days later, the patient’s general condition markedly deteriorated. The patient was highly febrile, tachycardiac, tachypneic, hypotensive, and shock developed. The patient was transferred immediately to the ICU; initial resuscitative measures were done including IV fluids, mechanical ventilation. Vancomycin at a dose of 15 mg/kg/6 hours was added to broaden the spectrum of antibiotics and continued for 8 days. After 24 hours of ICU admission, when the general condition permitted, follow-up CT maxillofacial and chest showed stationary course regarding the nodal and pulmonary lesions (Figure 1A and B, respectively). Initial blood and tracheal aspirate culture showed heavy growth of *Candida glabrata*; facial swab wound culture showed *Aspergillus flavus* (Figure 2A and B, respectively). At this point, caspofungin at a

![Figure 1](https://example.com/fig1.jpg)

**Figure 1.** (A) maxillofacial CT scan showing ulcerating lesion in the left inner canthus with erosion of the left nasal bone. Left intra-orbital upper lateral cystic lesion measuring 14 * 12 * 7 mm in its maximal diameters. (B) Well defined right side pulmonary nodule measuring 19*22 mm in maximal diameter.

![Figure 2](https://example.com/fig2.jpg)

**Figure 2.** (A) Early fungal after 24 hours, where growth is still not identified. (B) Late fungal growth after 90 hours of incubation 30°C in a humidified environment.
A dose of 70mg/m²/day was added to liposomal amphotericin B instead of fluconazole for 8 days. After 2 days, follow-up blood culture gave growth to *methicillin resistant Staphylococcus aureus*. The patient deteriorated gradually regarding pulmonary condition, ventilator demands increased and follow-up chest imaging revealed newly developed bilateral apical and basal consolidative patches. After 8 days of ICU admission, the patient developed multi-organ dysfunction syndrome secondary to sepsis leading to patient’s cardiac arrest with failed cardio-pulmonary resuscitation.

**Discussion**

This case describes mixed fungal infection in a severely immunocompromised patient after chemotherapy. The infection started local and superficial till ended up with candida septic shock. Early diagnosis of fungal infection is critical to effective treatment that improve the outcome. Diagnosis of fungal infection can be confirmed by either etiologic agent is isolated from clinical sterile specimens by culture or by histopathological diagnosis of a specimen or biopsy. In our case, we found it difficult to take any tissue biopsy due to rapid deterioration of patient’s general condition which is one of the limitations in our work. Mixed fungal infection is a rare condition, it was reported in 2014 in a case with severe hand injury after corrective surgery. Other study reported only three mixed fungal infections from 178 immunocompromised pneumonia patients.

Early and aggressive treatment of invasive fungal infection is very important to improve the outcome. A high index of suspicion is needed, especially with few antifungal agents available and increasing resistance. Early administration of antifungal combination may salvage the patient’s condition. But in our case the patient died due to his immunocompromised condition.

**Conclusion**

Neutropenic patients are greatly vulnerable to life threatening fungal infections. Aggressive, early administration of double antifungal drugs may be needed in mixed fungal infection.

**Data availability**

All data underlying the results are available as part of the article and no additional source data are required.

**Consent**

Written informed consent for publication of their clinical details and clinical images was obtained from the parents of the patient.

**References**

1. Neofytos D, Lu K, Hatfield-Seung A, et al.: Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy. *Diagn Microbiol Infect Dis.* 2013; 75(2):144–149. PubMed Abstract | Publisher Full Text | Free Full Text
2. Vitrat-Hincky V, Lebeau B, Bozonnet E, et al.: Severe filamentous fungal infections after widespread tissue damage due to traumatic injury: six cases and review of the literature. *Scandinavian Journal of Infectious Diseases.* 2009; 41(6–7):491–500. PubMed Abstract | Publisher Full Text
3. Hirano R, Sakamoto Y, Kudo K, et al.: Retrospective analysis of mortality and *Candida* isolates of 75 patients with candidemia: a single hospital experience. *Infect Drug Resist.* 2015; 8: 199–205. PubMed Abstract | Publisher Full Text | Free Full Text
4. Kozel TR, Wickes B: *Fungal diagnostics*. *Cold Spring Harb Perspect Med.* 2014; 4(4): a019299. PubMed Abstract | Publisher Full Text | Free Full Text
5. Badiee P, Hashemizadeh Z: Opportunistic invasive fungal infections: diagnosis & clinical management. *Indian J Med Res.* 2014; 139(2): 195–204. PubMed Abstract | Free Full Text
6. Milana Obradovic-Tomasev M, Popovic A, Vuckovic N, et al.: Mixed Fungal Infection (Aspergillus, Mucor, and Candida) of Severe Hand Injury. *Case Rep Infect Dis.* 2014; 2014: 954186. PubMed Abstract | Publisher Full Text | Free Full Text
7. Von Eiff M, Roos N, Fegeler W, et al.: Pulmonary fungal infections in immunocompromised patients: incidence and risk factors. *Mycoses.* 1994; 37(9–10): 329–35. PubMed Abstract | Publisher Full Text | Free Full Text
8. Badiee P, Alborzi A, Moeini M, et al.: Antifungal susceptibility of the *Aspergillus* species by Etest and CLSI reference methods. *Arch Iran Med.* 2012; 15(7): 429–32. PubMed Abstract
Open Peer Review

Current Peer Review Status: ? ?

[Image]

Version 1

Reviewer Report 15 February 2021

https://doi.org/10.5256/f1000research.22441.r79406

© 2021 Zawitkowska J. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Joanna Zawitkowska

Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 6 Antoni Gębala Str., Lublin, 20-093, Poland

This paper describes a facial mixed fungal infection in a poorly responding non-Hodgkin's lymphoma patient with suspected immunodeficiency. The fungal infection are still therapeutic problem in children with hematologic malignancies. The manuscript is potentially interesting, but requires a major revision.

Comment 1
- The manuscript should be edited for proper English language, grammar, punctuation, spelling, and overall style.

Comment 2
- Title: I suggest shortening the title.

Comment 3
- Abstract: "Candida glabrata, which is non-Candida albicans fungus was the fungus that appeared in the patient's blood culture." I suggest to remove ".....which is non-Candida albicans fungus". May be better: "The results of the patient's blood culture was Candida glabrata" or the like.

- "two days later, the follow up blood culture revealed growth of methicillin resistant" This sentence should be started from the capital letter.

Comment 4
- Introduction: the introduction contains too little information about this subject.

Comment 5
- Case reports: Has the patient received antifungal prophylaxis at the time of diagnosis and during the first course of chemotherapy.

- Was the patient undergoing a CT scan of chest at the time of diagnosis?

- It is unclear why the patient received Fluconazole only for 7 days?
Was GCS-F used during neutropenia?

Comment 6

- “Initial bone marrow aspirate and cerebrospinal fluid were normal with no infiltration with atypical cells.” I suggest to remove “were normal”, but “.... were no infiltrated by .....”

- CT – please, explain abbreviation

Comment 7

- Discussion: The article does not use the latest knowledge about this subject. In the literature used, all of the items are older than 5 years. This section is too short.

Is the background of the case’s history and progression described in sufficient detail?
Partly

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?
Partly

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?
No

Is the case presented with sufficient detail to be useful for other practitioners?
Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Hematologic malignacies, especially acute lymphoblastic leukemia

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
are few case reports of mixed fungal infections, such a report could provide information concerning to fungal therapy. I however believe the report would be more informative when the authors reveal the sensitivity of isolated fungi against used antifungals (fluconazole, amphotericinB, and Caspofungin) and compare them with their type culture strains.

**Is the background of the case's history and progression described in sufficient detail?**
Yes

**Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?**
Partly

**Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?**
Partly

**Is the case presented with sufficient detail to be useful for other practitioners?**
Yes

*Competing Interests:* No competing interests were disclosed.

*Reviewer Expertise:* Mycology and molecular biology.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com